Loading…
← CockpitCompetitor Analysis › SI Shoulder Innovations, Inc.Open in the cockpit ↗

Shoulder Innovations, Inc.SICompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum leader 90
Mkt cap
$428M
US dollars, full cap
Free float
55%
of shares outstanding
$/day
$1.93M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-75.4 pp
WACC 6.3%
Hurdle
n/a
no reverse DCF
Next earnings
130 days
16 Mar 2027
Close · USD$20.54
1D+0.8%
1W+7.4%
1M+14.8%
3M-1.0%
6M+55.6%
YTD+43.6%
1Y+81.9%
ATR %5.8%
Beta0.45
52w lowhigh16.5% off high

What Shoulder Innovations does

Employees: 75

Shoulder Innovations at a glance

Size Shoulder Innovations (SI) is a United States Health Care company (Medical Specialties) with a market value of $428M, the 2806th largest of 3,117 United States companies the cockpit tracks. Shares closed at $20.54 on 6 Nov 2026.

Performance Over six months the shares gained 55.6%, against -22.1% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 20 in its peer set.

Growth Revenue grew 60.9% over the last twelve months (peer median +10.8%); the operating margin is -58.5% (peer median 3.6%).

Valuation It trades at 5.7× enterprise value to sales against a peer median of 5.0× (8th most expensive of 21).

Capital Return on invested capital runs 75.4 points below its cost of capital (6.3% WACC).

Short interest Short interest is 3.4% of the free float (15 Oct 2026).

Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015011 May 202611 Aug 20266 Nov 2026SI 155Peer median 80
Six months, rebased to 100: Shoulder Innovations against the median of its 20 peers (local-currency closes).

Shoulder Innovations financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
Revenue$60.1M$47.3M$31.6M$19.3M
Revenue growth—+50%+64%—
Gross profit$42.4M$33.0M$22.1M$13.6M
EBITDA-$31.1M-$23.1M-$12.5M-$9.22M
Net income-$35.0M-$40.4M-$15.6M-$12.7M
Free cash flow-$47.6M-$36.0M-$18.2M-$15.9M
Capital expenditure$9.99M$7.41M$4.01M$2.75M
Total debt$14.8M$15.0M$14.7M$14.5M

Quarterly statements and history in the cockpit →

Shoulder Innovations competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-25%0%+25%NPCE688133SSIIYDESMASS605186300238688358458870688338CERSBWAY4685309877SI6-month return →1-month return →
Up and to the right = strong over both horizons. Shoulder Innovations is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%0×200×400×NPCE688133SSIIYDES4588703010974685309877SIRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shoulder Innovations is the large dot.

Shoulder Innovations competitors and peer comparison

How Shoulder Innovations compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shoulder Innovations against its 20 peers (data as of 6 Nov 2026)
MeasureSIPeer medianRank in peer set
1-month return+14.8%-12.7%2nd highest of 21
6-month return+55.6%-22.1%highest of 20
Distance from 52-week high-16.5%-40.9%highest of 21
Revenue growth (TTM)+60.9%+10.8%4th highest of 21
Operating margin-58.5%3.6%4th lowest of 21
EV / Sales5.7×5.0×8th most expensive of 21
ROIC minus cost of capital-75.4 pp-4.9 pplowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Shoulder Innovations SIUnited States$428M+56%+61%-59%5.7×n/an/a
NeuroPace NPCEUnited States$429M-32%+12%-15%4.5×n/an/a
Shanghai Titan Scientific 688133.SSChina$432M-22%-5%-5%1.5×n/an/a
SS Innovations International SSIIUnited States$423M-45%+90%-16%8.0×n/an/a
YD Bio YDESUnited States$423M-58%+17%-883%704.2×n/an/a
908 Devices MASSUnited States$436M+29%+1%-35%5.5×n/an/a
Shanghai General Healthy Information & Technology 605186.SSChina$417M+3%+12%6%8.1×55.5%+3.8%
Guanhao Biotech 300238.SZChina$440M-25%-7%5%7.8×n/an/a
Chison Medical Technologies 688358.SSChina$443M-16%-1%19%4.4×11.8%+5.6%
Medcaptain Medical Technology 2041.HKHong Kong$412Mn/a+19%3%1.6×23.3%+18.1%
SEERS 458870.KSSouth Korea$409M-70%+425%43%5.5×-9.1%+247.0%
Beijing Succeeder Technology 688338.SSChina$408M-15%-4%31%5.4×9.8%+3.4%
Cerus CERSUnited States$408M-23%+14%-12%1.9×n/an/a
Shanghai Kehua Bio-Engineering 002022.SZChina$407M-14%+3%-45%1.9×n/an/a
Ningbo Tianyi Medical Appliance 301097.SZChina$407M-20%+46%8%4.3×n/an/a
Brainsway Ltd Sponsored ADR BWAYUnited States$450M-35%+32%12%6.5×34.3%+18.8%
PROTEINA 468530.KSSouth Korea$450M-2%-59%-1,178%410.3×n/an/a
Guangdong Transtek Medical Electronics 300562.SZChina$406M-13%+7%11%2.0×-2.5%-6.0%
Hunan Sundy Science and Technology 300515.SZChina$453M-13%+10%27%3.7×0.9%+15.6%
Eiken Chemical 4549.TJapan$454M-29%+4%6%1.5×n/an/a
Jenscare Scientific 9877.HKHong Kong$463M-32%+993%-106%20.2×n/an/a

Questions

Which companies are Shoulder Innovations's closest peers?
The cockpit's peer set: NeuroPace (NPCE), Shanghai Titan Scientific (688133.SS), SS Innovations International (SSII), YD Bio (YDES), 908 Devices (MASS), Shanghai General Healthy Information & Technology (605186.SS), Guanhao Biotech (300238.SZ), Chison Medical Technologies (688358.SS).
Is Shoulder Innovations expensive compared with its peers?
On ev / sales it trades at 5.7× against a peer median of 5.0×, 8th most expensive of 21 in its peer set.
How has Shoulder Innovations stock performed?
Over six months to 6 Nov 2026 the shares returned +55.6% against -22.1% for the median peer; over one year +81.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.